OrbiMed Advisors LLC filed Q1 2026 13F: EWTX leads a $5B portfolio

Filed: 2026-05-15 · Report date: 2026-03-31 · Form: 13F-HR

Source: SEC EDGAR filing

Portfolio overview

Portfolio value: $5B
Holdings: 113
Previous quarter: 2025-12-31

Top 5 holdings

EWTX — $488.8M (9.7%)
ELVN — $312M (6.2%)
MDXH — $285.9M (5.7%)
LLY — $217.8M (4.3%)
SVA — $184.5M (3.7%)

New positions

MDXH — $285.9M (5.7%)
RCEL — $154.4M (3.1%)
AZN — $132.2M (2.6%)
MYGN — $122.9M (2.4%)
MRK — $79.8M (1.6%)

Exits

TERNS PHARMACEUTICALS INC — last seen at $87M
APELLIS PHARMACEUTICALS INC — last seen at $61M
THE CIGNA GROUP — last seen at $56.4M
RAPT THERAPEUTICS INC — last seen at $55.6M
UNITED THERAPEUTICS CORP DEL — last seen at $51.3M

Biggest adds

ELVN — +$189.4M (now $312M)
EWTX — +$103.7M (now $488.8M)
EW — +$85.8M (now $98.5M)

Biggest trims

LLY — -$105.9M (now $217.8M)
UPB — -$103.3M (now $51.2M)
BSX — -$81.2M (now $149.5M)

Methodology note

13F filings are public quarterly disclosures with up to a 45-day lag from quarter-end. Numbers here reflect the manager's disclosed long US equity positions only; they are not a real-time portfolio, do not include derivatives or short positions, and are not actual fund NAV. Not investment advice.

Full case file: https://worldsmartmoney.com/manager/orbimed

This article: https://worldsmartmoney.com/news/orbimed-2026-03-31-002369

English thread

Tweet 1/5 · 155 chars

OrbiMed Advisors LLC filed Q1 2026 13F.

Portfolio: $5B (113 holdings)
Top: EWTX $488.8M (9.7%)

https://worldsmartmoney.com/news/orbimed-2026-03-31-002369

Tweet 2/5 · 127 chars

Top 5 holdings:

1. EWTX $488.8M (9.7%)
2. ELVN $312M (6.2%)
3. MDXH $285.9M (5.7%)
4. LLY $217.8M (4.3%)
5. SVA $184.5M (3.7%)

Tweet 3/5 · 170 chars

Position changes from 2025-12-31:

🆕 New: MDXH, RCEL, AZN, MYGN
🚪 Exited: TERNS PHARMACEUTICALS INC, APELLIS PHARMACEUTICALS INC, THE CIGNA GROUP, RAPT THERAPEUTICS INC

Tweet 4/5 · 124 chars

📈 Biggest adds:
  ELVN +$189.4M
  EWTX +$103.7M
  EW +$85.8M

📉 Biggest trims:
  LLY -$105.9M
  UPB -$103.3M
  BSX -$81.2M

Tweet 5/5 · 238 chars

Source: SEC 13F (≤45-day disclosure lag, not real-time, not fund NAV).

SEC: https://www.sec.gov/Archives/edgar/data/1055951/000117266126002369/0001172661-26-002369-index.htm
WSM: https://worldsmartmoney.com/news/orbimed-2026-03-31-002369

Chinese thread

Tweet 1/5 · 136 chars

OrbiMed Advisors LLC 更新 2026 Q1 13F

组合：$5B（113 只持仓）
第一持仓：EWTX $488.8M（9.7%）

https://worldsmartmoney.com/news/orbimed-2026-03-31-002369

Tweet 2/5 · 115 chars

前 5 大持仓：

1. EWTX $488.8M（9.7%）
2. ELVN $312M（6.2%）
3. MDXH $285.9M（5.7%）
4. LLY $217.8M（4.3%）
5. SVA $184.5M（3.7%）

Tweet 3/5 · 143 chars

相比 2025-12-31 的变化：

🆕 新建仓：MDXH、RCEL、AZN、MYGN
🚪 清仓：TERNS PHARMACEUTICALS INC、APELLIS PHARMACEUTICALS INC、THE CIGNA GROUP、RAPT THERAPEUTICS INC

Tweet 4/5 · 107 chars

📈 加仓最多：
  ELVN +$189.4M
  EWTX +$103.7M
  EW +$85.8M

📉 减仓最多：
  LLY -$105.9M
  UPB -$103.3M
  BSX -$81.2M

Tweet 5/5 · 207 chars

来源：SEC 13F（最多滞后 45 天公开，非实时，不代表基金净值）

SEC 原文：https://www.sec.gov/Archives/edgar/data/1055951/000117266126002369/0001172661-26-002369-index.htm
WSM 解读：https://worldsmartmoney.com/news/orbimed-2026-03-31-002369

13F is a quarterly disclosure with up to 45-day lag. Not real-time, not fund NAV, not investment advice.